Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

AMSTERDAM--(BUSINESS WIRE)--Nov 18, 2025--

Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/

The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio.

Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings together commercial excellence, scientific expertise, and deep functional capability across market access, pricing and reimbursement. This fully integrated approach enables biotech and pharma innovators to bring rare disease medicines to patients across all 32 European markets – an area where traditional go-to-market models often fail.

“We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite,” said Adam Plich, Founder and CEO of Avanzanite. “With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey,” concluded Plich.

In just three years, with three strategic alliances, Avanzanite has become the partner of choice for biotech and pharma innovators seeking to unlock the full European potential of their orphan medicines. Avanzanite’s current portfolio comprises three medicines across nephrology, ophthalmology and haematology with exclusive licensing or distribution rights in countries across the European Economic Area, the UK and Switzerland.

MVM is investing up to €32 million from its €500 million sixth fund. In addition, MVM has reserved significant capital to drive Avanzanite’s growth beyond the current round. MVM is Avanzanite’s first institutional investor and joins the company’s Board of Directors.

Dr. Jack Tanaka, Partner at MVM commented, “For years MVM has watched promising rare disease medicines struggle to find a path to patients - Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.”

About Avanzanite Bioscience

Avanzanite redefines launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, we partner with biotech and pharma innovators to unlock the full value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe’s complex landscape like master chess players – ensuring no patient is left behind while rewarding biotech and pharma innovators for their commitment to developing breakthrough therapies. For more information, visit www.avanzanite.com

About MVM Partners

MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston, London and the San Francisco Bay Area, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com

Jack Tanaka, MVM Partner.

Adam Plich, Founder and CEO of Avanzanite.

LONDON (AP) — The new head of the MI6 spy agency is set to warn on Monday of how Russian President Vladimir Putin’s determination to export chaos around the world is rewriting the rules of conflict and creating new security challenges.

Blaise Metreweli will use her first public speech as chief of the United Kingdom’s foreign intelligence service to say that Britain faces increasingly unpredictable and interconnected threats, with emphasis on “aggressive, expansionist” Russia.

“The export of chaos is a feature not a bug in the Russian approach to international engagement, and we should be ready for this to continue until Putin is forced to change his calculus,” she will say, according to extracts released by the Foreign Office, which oversees MI6.

The MI6 chief, known as C, is the only employee of the secretive agency whose name is made public. Metreweli, who took over from Richard Moore at the end of September, was previously the MI6 director of technology and innovation — the real-world equivalent of the fictional James Bond gadget-master Q.

She plans to say that technological savvy and human intelligence are both key to combating hybrid threats, and MI6 officers “must be as comfortable with lines of code as we are with human sources, as fluent in Python as we are in multiple languages.”

The speech is the latest in a series of warnings by Western defense and security authorities about the growing hybrid threat from states such as Russia, Iran and China, whose use of cyber tools, espionage and influence operations they say threatens global stability.

Last week, the U.K. imposed sanctions on several Russian media outlets for alleged information warfare and two Chinese tech firms for “vast and indiscriminate cyber-activities.”

Metreweli is the first woman to hold the post since MI6 was founded in 1909.

Britain’s two other main intelligence agencies have already shattered the spy world’s glass ceiling. MI5, the domestic security service, was led by Stella Rimington from 1992 to 1996 and Eliza Manningham-Buller between 2002 and 2007. Anne Keast-Butler became head of the electronic and cyberintelligence agency GCHQ in 2023.

The spy chief’s warning came amid a flurry of diplomatic meetings aimed at ending the almost four-year war sparked by Russia’s invasion of its neighbor.

Ukrainian President Volodymyr Zelenskyy met U.S. envoys on Sunday in Berlin, and will meet later with the leaders of Germany, France and Britain. Kyiv’s allies are trying to bolster support for Ukraine amid Washington’s pressure to swiftly accept a U.S.-brokered peace deal.

In a separate speech, the head of the British military, Air Chief Marshal Richard Knighton, will say Monday that Putin’s aim is “to challenge, limit, divide and ultimately destroy NATO.”

“The war in Ukraine shows Putin’s willingness to target neighboring states, including their civilian populations ... threatens the whole of NATO, including the U.K.,” Knighton plans to say, arguing that Britain needs both a stronger military and more resilient infrastructure to meet the evolving threat.

FILE - A general view of the headquarters of the Secret Intelligence Service, MI6, in London, March 18, 2025. (AP Photo/Kin Cheung, File)